Plain-English translation of NCT05357612 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This research study is testing how works in the brain to reduce psychosis symptoms—like hallucinations and delusions—in people with Parkinson's disease and other neurodegenerative conditions. Researchers will use special brain imaging scans (PET and MRI) to see how the medication changes brain activity and receptor activity over 6 weeks of treatment. By understanding these brain changes, doctors hope to better explain why this medication helps some patients.
Psychosis in Parkinson's disease and similar conditions can be very difficult to treat and deeply troubling for patients and families. Doctors know this medication helps some people, but they don't fully understand how it works in the brain—filling this gap could help improve treatment for future patients.
You likely qualify if…
You likely don't qualify if…
You would visit the research center at baseline and again after 6 weeks of taking the medication . At each visit, you'll have a PET brain scan (a special imaging test that measures brain chemistry) and an MRI brain scan (which shows brain structure and activity). You'll also complete some memory and thinking tests. A study partner will need to accompany you to these visits to help with consent and support. The whole process takes about 6 weeks, with two main imaging visits.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States